Masters athlete screening study (MASS): incidence of cardiovascular disease and major adverse cardiac events and efficacy of screening over five years
Authors' conclusion
MACE occurred despite yearly screening. All MAs who had an event had an abnormal screen; however, cardiac functional tests failed to detect underlying CAD in most cases.
Study context
- Population
- Masters athletes (≥35 y) without previous history of cardiovascular disease (CVD)62.7% male, 55 ± 10 y
- Participants
- 798 athletes
- Outcome
- Effectiveness of yearly CV screening; incidence of CVD and MACE
- Follow-up
- Five years
Methodological detailsyearly cardiovascular screening, 5-year follow-up
- Yearly cardiovascular screening
- 5-year follow-up
Main finding
As reported in the abstract
- CVD diagnosed at initial screening
- 11.4% (n = 91)
- Coronary artery disease (CAD) most common initial diagnosis
- n = 64; 53%
- Additional CVD diagnoses during follow-up
- 89
- CVD incidence rate, years one to four
- 3.58/100, 4.14/100, 3.74/100, 1.19/100
- Arrhythmias most common follow-up diagnosis
- n = 33; 37%
- MACE
- Ten MACE (2.8/1000 athlete-years)
- MACE: all male; ≥10% Framingham Risk Score (FRS)
- 90%
- MACE: obstructive CAD identified on further evaluation
- 2
Observational data: associations, not effects.
Further findings
Predictors of CAD
| OR (95% CI) | P value | ||
|---|---|---|---|
| Increasing age | 1.047 (1.003–1.094) | P = 0.0379 | |
| Framingham Risk Score | 1.092 (1.031–1.158) | P = 0.003 | |
| LDL cholesterol | 1.709 (1.223–2.401) | P = 0.002 | |
| Moderate intensity activity (min/wk)Protective | 0.997 (0.996–0.999) | P = 0.002 | |
| 0.512Odds ratio (log scale) |
Original publication
Masters athlete screening study (MASS): incidence of cardiovascular disease and major adverse cardiac events and efficacy of screening over five years. Eur J Prev Cardiol. Published 22 March 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →